Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Journal

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PPO.0b013e31818d8178PMID 19060598
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interphase Cytogenetics for 1p19q and t(1;19)(q10;p10) may Distinguish Prognostically Relevant Subgroups in Extraventricular Neurocytoma

  2009cited by this paper
• Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile

  2008cited by this paper
• The 2007 WHO classification of tumors of the central nervous system – what has changed?

  2008cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome

  2007cited by this paper
• Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

  2007cited by this paper
• A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

  2006cited by this paper
• High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.

  2006cited by this paper
• Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

  2006cited by this paper
• Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.

  2006cited by this paper
• Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

  2006cited by this paper
• Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

  2006cited by this paper
• Identification of der(1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss

  2006cited by this paper
• Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors

  2006cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy

  2004cited by this paper
• Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas

  2004cited by this paper
• Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors.

  2004cited by this paper
• Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

  2003influential reference
• Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

  2003cited by this paper
• Oligodendroglioma: pathology and molecular biology.

  2002cited by this paper
• Biology of oligodendrocyte and myelin in the mammalian central nervous system.

  2001cited by this paper
• Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

  2001cited by this paper
• Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

  2000cited by this paper
• Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

  1998cited by this paper
• Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

  1994cited by this paper
• Immunohistochemical and Ultrastructural Studies of Oligodendrogliomas Revealed Features of Neuronal Differentiation

  1994cited by this paper
• Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

  1994cited by this paper
• Successful chemotherapy for recurrent malignant oligodendroglioma

  1988cited by this paper
• Oligodendrogliomas of the brain

  1929cited by this paper

• NFKBIE as a prognostic biomarker and therapeutic target for GBM: role in Hedgehog signaling activation

  2025cites this paper
• Impact of Hypertension on the Outcomes of Patients With High-Grade Gliomas: A Propensity-Matched Study From a Global Federated Health Research Network

  2025cites this paper
• PMFN-SSL: Self-supervised learning-based progressive multimodal fusion network for cancer diagnosis and prognosis

  2024cites this paper
• Macrophage polarization‐related gene signature for risk stratification and prognosis of survival in gliomas

  2024cites this paper
• A rare, giant, anaplastic oligodendroglioma

  2023cites this paper
• Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization (FISH) as prognostic factors in malignant glioma patients on treatment with alkylating chemotherapy.

  2023cites this paper
• Global and Gender Equity in Oligodendroglioma Research: A Comprehensive Bibliometric Analysis Following the COVID-19 Pandemic

  2023cites this paper
• Cancer Registration, Molecular Marker Status, and Adherence to the WHO 2016 Classification of Pathology Reports for Glioma Diagnosed during 2017–2019 in Belgium

  2023cites this paper
• Chromatin structure predicts survival in glioma patients

  2022cites this paper
• Consequences of Chromosome Loss: Why Do Cells Need Each Chromosome Twice?

  2022cites this paper
• Identifying the Predictive Role of Oxidative Stress Genes in the Prognosis of Glioma Patients

  2021cites this paper
• Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion

  2021cites this paper
• Recurrent Glioblastoma is Associated with a Closed DNA Conformation

  2021cites this paper
• A Novel Ferroptosis-related Gene Signature for Prognosis Prediction in Glioma

  2021cites this paper
• Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma

  2021cites this paper
• Artificial intelligence in glioma imaging: challenges and advances

  2019cites this paper
• Applying Artificial Intelligence to Glioma Imaging: Advances and Challenges

  2019cites this paper
• The surgical perspective in precision treatment of diffuse gliomas

  2019cites this paper
• Frameless stereotactic biopsy for precision neurosurgery: diagnostic value, safety, and accuracy

  2019cites this paper
• Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors

  2019cites this paper
• Oligodendroglioma WHO Grade II-​Anaplastic Oligodendroglioma WHO Grade III

  2019cites this paper
• Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics

  2019cites this paper
• [The 2016 WHO classification of primary central nervous system tumors: a clinician's view].

  2018cites this paper
• The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review.

  2018cites this paper
• Neoplasms of Central Nervous System: A Diagnostic Approach

  2018cites this paper
• Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors

  2018cites this paper
• Brain tumors - other treatment modalities.

  2017cites this paper
• Reappraising the 2016 WHO classification for diffuse glioma.

  2017cites this paper
• Genetic landscape of extreme responders with anaplastic oligodendroglioma

  2017cites this paper
• High expression of TIG3 predicts poor survival in patients with primary glioblastoma

  2017cites this paper
• Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response

  2017cites this paper
• Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas

  2016cites this paper
• Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.

  2016cites this paper
• Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines

  2016cites this paper
• Quantitative Measurement of Oligodendrogliomas Histologica Features inPredicting the 1p/19q Co-Deletion Status

  2016cites this paper
• CHARLES UNIVERSITY FACULTY OF MEDICINE IN PILSEN

  2016influential citation
• Évaluation préopératoire comparative de 43 gliomes de grade II et III par TEP au 18F-FDG et à la 18F-DOPA : corrélation aux données histologiques et moléculaires

  2016cites this paper
• Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic

  2016cites this paper
• The Evolving Molecular Genetics of Low-grade Glioma

  2015cites this paper
• Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm

  2015cites this paper
• Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.

  2015cites this paper
• Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.

  2015cites this paper
• CIC Mutation as Signature Alteration in Oligodendroglioma

  2015cites this paper
• Isocitrate Dehydrogenase (IDH) Mutation in Gliomas

  2015cites this paper
• TERT promoter mutations contribute to subset prognostication of lower-grade gliomas

  2015cites this paper
• IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas

  2015cites this paper
• Anti-cancer effects and mechanism of actions of aspirin-like drugs in the treatment of gliomas

  2015cites this paper
• Molecular biology techniques for loss of heterozygosity detection: the glioma example

  2015cites this paper
• Landscape of chromosomal copy number aberrations in gangliogliomas and dysembryoplastic neuroepithelial tumours

  2015cites this paper
• Using the molecular classification of glioblastoma to inform personalized treatment

  2014cites this paper
• Velmi pozdní následky radioterapie – limitující faktor současných radioterapeutických technik

  2014cites this paper
• Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

  2014cites this paper
• Molecular Pathology and Diagnostics of Gliomas

  2014cites this paper
• Section III: molecular diagnostics in neuro-oncology.

  2014cites this paper
• ImmunoFISH Is a Reliable Technique for the Assessment of 1p and 19q Status in Oligodendrogliomas

  2014cites this paper
• Molecular Cytogenetic Analysis of Chromosomal Aberrations in Cells of Low Grade Gliomas and Its Contribution for Tumour

  2014influential citation
• Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment

  2014cites this paper
• New treatment paradigm for patients with anaplastic oligodendroglial tumors.

  2014cites this paper
• Diagnostic and prognostic markers in gliomas – an update

  2013cites this paper
• Comparative expression analysis reveals lineage relationships between human and murine gliomas and a dominance of glial signatures during tumor propagation in vitro.

  2013cites this paper
• Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma.

  2013cites this paper
• Lrig2-Deficient Mice Are Protected against PDGFB-Induced Glioma

  2013cites this paper
• Adult Low-grade Glioma: 19-year Experience at a Single Institution

  2013cites this paper
• What is the clinical value of cancer stem cell markers in gliomas?

  2013cites this paper
• Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis

  2013cites this paper
• Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution

  2013cites this paper
• Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

  2013cites this paper
• 11C-Methionine Uptake Correlates with Combined 1p and 19q Loss of Heterozygosity in Oligodendroglial Tumors

  2013cites this paper
• [Clinico-pathological and molecular aspects of diagnostic and prognostic value in gliomas].

  2013cites this paper
• Novel CIC Point Mutations and an Exon-Spanning, Homozygous Deletion Identified in Oligodendroglial Tumors by a Comprehensive Genomic Approach Including Transcriptome Sequencing

  2013cites this paper
• Value of 11C-methionine PET in imaging brain tumours and metastases

  2013cites this paper
• Molecular classification of diffuse gliomas.

  2013cites this paper
• Genotype-phenotype studies in brain tumors

  2013cites this paper
• Studies on the Roles of PDGFRA and EGFR in the Classification and Identification of Therapeutic Targets for Human Gliomas

  2013cites this paper
• Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.

  2013cites this paper
• Genetics of adult glioma.

  2012cites this paper
• CIC and FUBP1 mutations in oligodendroglioma.

  2012cites this paper
• Biomarkers usher in era of personalized care for malignant glioma patients.

  2012cites this paper
• Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

  2012cites this paper
• Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas

  2012cites this paper
• Molecular markers of glioma: an update on recent progress and perspectives

  2012cites this paper
• Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies

  2012cites this paper
• Non-Gaussian Distributions Affect Identification of Expression Patterns, Functional Annotation, and Prospective Classification in Human Cancer Genomes

  2012cites this paper
• Molecular Subtypes of Gliomas

  2011cites this paper
• Définition d’une glyco-signature spécifique des cellules souches tumorales de glioblastome et développement d’outils pour la caractérisation cellulaire

  2011cites this paper
• Targeted Therapy for Malignant Gliomas

  2011cites this paper
• Risk factors for oligodendroglial tumors: a pooled international study.

  2011cites this paper
• Evolvement of Molecular Biomarkers in Targeted Therapy of Malignant Gliomas

  2011cites this paper
• Molecular diagnostics of gliomas.

  2011cites this paper
• One Hundred and One Dysembryoplastic Neuroepithelial Tumors: An Adult Epilepsy Series With Immunohistochemical, Molecular Genetic, and Clinical Correlations and a Review of the Literature

  2011cites this paper
• Design of clinical trials for biomarker research in oncology.

  2011cites this paper
• Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

  2011cites this paper
• Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.

  2010cites this paper
• Anaplastic oligodendrogliomas after treatment of acute lymphoblastic leukemia in children: report of 2 cases.

  2010cites this paper
• Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas

  2009cites this paper
• A silver lining on the horizon for glioblastoma.

  2009cites this paper